BACTERIAL SEPSIS AND MENINGITIS - Nizet Laboratory at UCSD

[667] E. Wald, et al., Long-term outcome of group B streptococcal meningitis,
Pediatrics 77 (1986) 217.
[668] S.M. Franco, V.E. Cornelius, B.F. Andrews, Long-term outcome of neonatal
meningitis, Am. J. Dis. Child. 146 (1992) 567.
[669] K.A. Horn, et al., Neurological sequelae of group B streptococcal neonatal
infection, Pediatrics 53 (1974) 501.
[670] M.S. Edwards, et al., Long-term sequelae of group B streptococcal meningitis
in infants, J. Pediatr. 106 (1985) 717.
[671] G.H. McCracken Jr., et al., Cerebrospinal fluid interleukin-1B and tumor
necrosis factor concentrations and outcome from neonatal gram-negative
enteric bacillary meningitis, Pediatr. Infect. Dis. J. 8 (1989) 155.
[672] G.H. McCracken Jr., et al., Moxalactam therapy for neonatal meningitis due
to gram-negative enteric bacilli: a prospective controlled evaluation, JAMA
252 (1984) 1427.
[673] J. Baier, J.A. Bocchini Jr., E.G. Brown, Selective use of vancomycin to prevent
coagulase-negative staphylococcal nosocomial bacteremia in high risk
very low birth weight infants, Pediatr. Infect. Dis. J. 17 (1998) 179.
[674] R.W. Cooke, et al., Low-dose vancomycin prophylaxis reduces coagulasenegative
staphylococcal bacteraemia in very low birthweight infants, J. Hosp.
Infect. 37 (1997) 297–303.
[675] M.A. Kacica, et al., Prevention of gram-positive sepsis in neonates weighing
less than 1500 grams, J. Pediatr. 125 (1994) 253–258.
[676] P.S. Spafford, et al., Prevention of central venous catheter-related coagulasenegative
staphylococcal sepsis in neonates, J. Pediatr. 125 (1994) 259–263.
[677] A.P. Craft, N.N. Finer, K.J. Barrington, Vancomycin for prophylaxis against
sepsis in preterm neonates, Cochrane Database Syst. Rev. CD001971, (2000).
[678] J.S. Garland, et al., A vancomycin-heparin lock solution for prevention of
nosocomial bloodstream infection in critically ill neonates with peripherally
inserted central venous catheters: a prospective, randomized trial, Pediatrics
116 (2005) e198–e205.
[679] P. Van de Perre, Transfer of antibody via mother’s milk, Vaccine 21 (2003) 3374.
[680] L.A. Hanson, et al., Antiviral and Antibacterial Factors in Human Milk,
Raven Press, New York, 1988.
[681] N.B. Mathus, et al., Anti-infective factors in preterm human colostrum, Acta
Paediatr. Scand. 79 (1990) 1039.
[682] C.F. Isaacs, et al., Antiviral and antibacterial lipids in human milk and infant
formula feeds, Arch. Dis. Child. 65 (1990) 861.
[683] J. Winberg, G. Wessner, Does breast milk protect against septicaemia in the
newborn? Lancet 1 (1971) 1091.
[684] R.N. Ashraf, et al., Breast feeding and protection against neonatal sepsis in a
high risk population, Arch. Dis. Child. 66 (1991) 488.
[685] M.A. Hylander, D.M. Strobino, R. Dhanireddy, Human milk feedings and
infection among very low birth weight infants, Pediatrics 102 (1998) E38.
[686] G.V. Coppa, et al., Preliminary study of breastfeeding and bacterial adhesion
to uroepithelial cells, Lancet 1 (1990) 569.
[687] H. Hasselbalch, et al., Decreased thymus size in formula-fed infants compared
with breastfed infants, Acta Paediatr. 85 (1996) 1029–1032.
[688] H.F. Pabst, et al., Effect of breast-feeding on immune response to BCG
vaccination, Lancet 1 (1989) 295.
[689] S.A. Silfverdal, et al., Long term enhancement of the IgG2 antibody
response to Haemophilus influenzae type b by breast-feeding, Pediatr. Infect.
Dis. J. 21 (2002) 816–821.
[690] M. Cohen-Wolkowiez, D.K. Benjamin Jr., E. Capparelli, Immunotherapy in
neonatal sepsis: advances in treatment and prophylaxis, Curr. Opin. Pediatr.
21 (2009) 177–181.
[691] J.A. Englund, W.P. Glezen, Maternal immunization for the prevention of
infection in early infancy, Semin. Pediatr. Infect. Dis. 2 (1991) 225.
[692] M. Vicari, B. Dodet, J. Englund, Protection of newborns through maternal
immunization, Vaccine 21 (2003) 3351.
[693] C.J. Baker, M.A. Rench, P. McInnes, Immunization of pregnant women with
group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate
vaccine, Vaccine 21 (2003) 3468.
[694] A.A. Fanaroff, et al., A controlled trial of intravenous immune globulin to
reduce nosocomial infections in very-low-birth-weight infants. National
Institute of Child Health and Human Development Neonatal Research
Network, N. Engl. J. Med. 330 (1994) 1107–1113.
[695] M. DeJonge, et al., Clinical trial of safety and efficacy of INH-A21 for the
prevention of nosocomial staphylococcal bloodstream infection in premature
infants, J. Pediatr. 151 (2007) 260.
[696] D.K. Benjamin, et al., A blinded, randomized, multicenter study of an
intravenous Staphylococcus aureus immune globulin, J. Perinatol. 26 (2006)
290–295.
[697] A. Ohlsson, J.B. Lacy, Intravenous immunoglobulin for preventing infection
in preterm and/or low-birth-weight infants, Cochrane Database Syst. Rev.
CD000361, (2004).
[698] D. Sidiropoulos, et al., Transplacental passage of intravenous immunoglobulin
in the last trimester of pregnancy, J. Pediatr. 109 (1986) 505.
[699] E. Roilides, P.A. Pizzo, Modulation of host defenses by cytokines: evolving
adjuncts in prevention and treatment of serious infections in immunocompromised
patients, Clin. Infect. Dis. 15 (1992) 508.
[700] R.L. Roberts, et al., Neutropenia in an extremely premature infant treated
with recombinant human granulocyte colony-stimulating factor, Am. J.
Dis. Child. 145 (1991) 808.
[701] M.S. Cairo, et al., A randomized, double-blind, placebo-controlled trial of prophylactic
recombinant human granulocyte-macrophage colony-stimulating
CHAPTER 6 Bacterial Sepsis and Meningitis
277
factor to reduce nosocomial infections in very low birth weight neonates,
J. Pediatr. 134 (1999) 64.
[702] K.D. Yang, F.J. Bohnsack, H.R. Hill, Fibronectin in host defense: implications
in the diagnosis, prophylaxis and therapy of infectious diseases, Pediatr.
Infect. Dis. J. 12 (1993) 234.
[703] M.C. Yoder, Therapeutic administration of fibronectin: current uses and
potential applications, Clin. Perinatol. 18 (1991) 325.
[704] R. Carr, et al., Granulocyte-macrophage colony stimulating factor administered
as prophylaxis for reduction of sepsis in extremely preterm, small for
gestational age neonates (the PROGRAMS trial): a single-blind, multicentre,
randomised controlled trial, Lancet 373 (2009) 226–233.
[705] M. Donini, et al., G-CSF treatment of severe congenital neutropenia
reverses neutropenia but does not correct the underlying functional deficiency
of the neutrophil in defending against microorganisms, Blood
109 (2007) 4716–4723.
[706] B.B. Poindexter, et al., Parenteral glutamine supplementation does not
reduce the risk of mortality or late-onset sepsis in extremely low birth weight
infants, Pediatrics 113 (2004) 1209–1215.
[707] T.R. Tubman, S.W. Thompson, W. McGuire, Glutamine supplementation
to prevent morbidity and mortality in preterm infants, Cochrane Database
Syst. Rev. CD001457, (2008).
[708] H.C. Lin, B.H. Su, W. Oh, Oral probiotics prevent necrotizing enterocolitis,
J. Pediatr. 148 (2006) 849.
[709] H.C. Lin, et al., Oral probiotics reduce the incidence and severity of necrotizing
enterocolitis in very low birth weight infants, Pediatrics 115 (2005) 1–4.
[710] P. Manzoni, et al., Oral supplementation with Lactobacillus casei subspecies
rhamnosus prevents enteric colonization by Candida species in preterm neonates:
a randomized study, Clin. Infect. Dis. 42 (2006) 1735–1742.
[711] K. Alfaleh, J. Anabrees, D. Bassler, Probiotics reduce the risk of necrotizing
enterocolitis in preterm infants: a meta-analysis, Neonatology 97 (2009) 93–99.
[712] N. Orsi, The antimicrobial activity of lactoferrin: current status and perspectives,
Biometals 17 (2004) 189–196.
[713] J.J. Damato, D.V. Eitzman, H. Baer, Persistence and dissemination in the
community of R-factors of nosocomial origin, J. Infect. Dis. 129 (1974) 205.
[714] J.O. Klein, Family spread of staphylococcal disease following a nursery outbreak,
N. Y. State. J. Med. 60 (1960) 861.
[715] N. Nakwan, T. Atta, K. Chokephaibulkit, Neonatal pasteurellosis: a review
of reported cases, Arch. Dis. Child. Fetal Neonatal Ed. 94 (2009)
F373–F376.
[716] S.A. Bhave, L.M. Guy, Pasteurella multocida meningitis in an infant with
recovery, BMJ 2 (1977) 741.
[717] C. Guillet, et al., Pasteurella multocida sepsis and meningitis in 2-month-old
twin infants after household exposure to a slaughtered sheep, Clin. Infect.
Dis. 45 (2007) e80–e81.
[718] T.F. Wolfs, et al., Neonatal sepsis by Campylobacter jejuni: genetically proven
transmission from a household puppy, Clin. Infect. Dis. 32 (2001) E97–E99.
[719] L.J. Baraff, et al., Practice guideline for the management of infants and children
0 to 36 months of age with fever without source. Agency for Health
Care Policy and Research, Ann. Emerg. Med. 22 (1993) 1198.
[720] M.D. Baker, Evaluation and management of infants with fever, Pediatr. Clin.
North. Am. 46 (1999) 1061.
[721] P.C. Ferrera, J.M. Bartfield, H.S. Snyder, Neonatal fever: utility of the
Rochester criteria in determining low risk for serious bacterial infections,
Am. J. Emerg. Med. 15 (1997) 299.
[722] R. Dagan, et al., Ambulatory care of febrile infants younger than 2 months of
age classified as being at low risk for having serious bacterial infections,
J. Pediatr. 112 (1988) 355.
[723] J.C. King Jr., E.D. Berman, P.F. Wright, Evaluation of fever in infants less
than 8 weeks old, South. Med. J. 80 (1987) 948.
[724] J.O. Klein, P.C. Schlessinger, R.B. Karasic, Management of the febrile infant
under three months of age, Pediatr. Infect. Dis. J. 3 (1984) 75.
[725] P. Ishimine, Fever without source in children 0 to 36 months of age, Pediatr.
Clin. North. Am. 53 (2006) 167–194.
[726] M.D. Baker, L.M. Bell, Unpredictability of serious bacterial illness in febrile
infants from birth to 1 month of age, Arch. Pediatr. Adolesc. Med.
153 (1999) 508–511.
[727] H.A. Kadish, et al., Applying outpatient protocols in febrile infants 1-28 days
of age: can the threshold be lowered? Clin. Pediatr. (Phila) 39 (2000) 81–88.
[728] M.D. Baker, L.M. Bell, J.R. Avner, Outpatient management without antibiotics
of fever in selected infants, N. Engl. J. Med. 329 (1993) 1437–1441.
[729] M.N. Baskin, E.J. O’Rourke, G.R. Fleisher, Outpatient treatment of febrile
infants 28 to 89 days of age with intramuscular administration of ceftriaxone,
J. Pediatr. 120 (1992) 22–27.
[730] B.K. Bonsu, M. Chb, M.B. Harper, Identifying febrile young infants with
bacteremia: is the peripheral white blood cell count an accurate screen?
Ann. Emerg. Med. 42 (2003) 216–225.
[731] L. Brown, T. Shaw, W.A. Wittlake, Does leucocytosis identify bacterial
infections in febrile neonates presenting to the emergency department?
Emerg. Med. J. 22 (2005) 256–259.
[732] D.S. Greenes, M.B. Harper, Low risk of bacteremia in febrile children with
recognizable viral syndromes, Pediatr. Infect. Dis. J. 18 (1999) 258–261.
[733] D.A. Levine, et al., Risk of serious bacterial infection in young febrile infants
with respiratory syncytial virus infections, Pediatrics 113 (2004) 1728–1734.
[734] W.I. Krief, et al., Influenza virus infection and the risk of serious bacterial
infections in young febrile infants, Pediatrics 124 (2009) 30–39.